TIMI Risk Score for STEMI estimates mortality in patients with STEMI Myocardial Infarction.
JVD or any pulmonary exam findings of CHF:
|Patient’s score||Risk of all-cause mortality at 30 days|
Addition of the assigned points.
|Age < 65 years||0|
|Age ≥ 75||+3|
|DM or Hypertension or Angina||+1|
|Systolic BP < 100 mmHg||+3|
|Heart Rate > 100||+2|
|Killip Class II-IV||+2|
|Weight < 67kg (147.7 lbs)||+1|
|Anterior ST Elevation or LBBB||+1|
|Time to Treatment > 4 hours||+1|
Interpretation of the results:
|Score||Risk of all-cause mortality at 30 days|
The patient’s with an ST-Elevation Myocardial Infarction (STEMI) are already at high risk for complications and adverse outcomes, including death. This score was developed based on outcomes analyses in patient’s after thrombolytic therapy, which likely have worse outcomes when compared to PCI. The TIMI Score for STEMI was developed from the InTIME II trial of 15,000 STEMI patients and was studying these patients for thrombolytics.
The primary endpoint was 30-day all-cause mortality and did not include a placebo arm.
TIMI Risk Score for STEMI should be used in patients with diagnosed STEMI, not to evaluate patients with chest pain.
STEMI patients should receive guidelines recommended treatment, obviously undergo PCI or thrombolysis, depending on availability and standard of care at one’s hospital; risk stratification can be performed only after this most critical first step.
David A. Morrow, et. al. TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation: An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy Circulation. 2000; 102: 2031-2037 doi: 10.1161/01.CIR.102.17.2031 https://pubmed.ncbi.nlm.nih.gov/11044416/
Morrow DA, Antman EM, Parsons L, et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA. 2001;286(11):1356-9. https://pubmed.ncbi.nlm.nih.gov/11560541/
Bradshaw PJ, Ko DT, Newman AM, Donovan LR, Tu JV. Validation of the Thrombolysis In Myocardial Infarction (TIMI) risk index for predicting early mortality in a population-based cohort of STEMI and non-STEMI patients. Can J Cardiol. 2007;23(1):51-6. https://pubmed.ncbi.nlm.nih.gov/17245483/
Silveira DS, Jaeger CP et al. Validation of TIMI risk score for STEMI. International Journal of Cardiovascular Sciences. 2016;29(3):189-197. http://www.onlineijcs.org/sumario/29/pdf/en_v29n3a06.pdf
Register on our website right now to have access to more learning materials!
Related interactive simulators:
AMEE 2023 took place from 26-30 August 2023 at the Scottish Event Campus (SEC), Glasgow,…
We are thrilled to announce that our Simulation Training Platform “ClinCaseQuest” has been featured on…
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies (Anthracycline Chemotherapy) – Online Calculator
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies (Anthracycline Chemotherapy)…
The National Institutes of Health Stroke Scale (NIHSS) is a scale designed to assess the…
We are at SESAM 2023 with oral presentation “Stage Debriefing in Simulation Training in Medical…
Charlson Comorbidity Index predicts 10-year survival in patients with multiple comorbidities.